These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 28842986)
1. Biosimilars: Key regulatory considerations and similarity assessment tools. Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986 [TBL] [Abstract][Full Text] [Related]
2. Biosimilars: A consideration of the regulations in the United States and European union. Daller J Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800 [TBL] [Abstract][Full Text] [Related]
3. FDA's Approach to Regulating Biosimilars. Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906 [TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? Hung A; Vu Q; Mostovoy L J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975 [TBL] [Abstract][Full Text] [Related]
6. The complexities of biosimilars and the regulatory approval process. Lucio S Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908 [TBL] [Abstract][Full Text] [Related]
8. Clinical considerations for the development of biosimilars in oncology. Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D MAbs; 2015; 7(2):286-93. PubMed ID: 25621390 [TBL] [Abstract][Full Text] [Related]
9. Biosimilars: Here and Now. Lemery SJ; Esteva FJ; Weise M Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717 [TBL] [Abstract][Full Text] [Related]
10. The US approach to biosimilars: the long-awaited FDA approval pathway. Calvo B; Zuñiga L BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars: The US Regulatory Framework. Christl LA; Woodcock J; Kozlowski S Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877 [TBL] [Abstract][Full Text] [Related]
12. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. Cuellar S; McBride A; Medina P Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935 [TBL] [Abstract][Full Text] [Related]
13. Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications - an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis. Hufnagel HR; Tennyson SD Expert Opin Biol Ther; 2024 Jul; 24(7):627-635. PubMed ID: 38962838 [TBL] [Abstract][Full Text] [Related]
14. Biosimilars: Rationale and current regulatory landscape. Olech E Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438 [TBL] [Abstract][Full Text] [Related]
15. Considerations in the early development of biosimilar products. Li EC; Abbas R; Jacobs IA; Yin D Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407 [TBL] [Abstract][Full Text] [Related]
16. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Ahmed I; Kaspar B; Sharma U Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050 [TBL] [Abstract][Full Text] [Related]
17. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J MAbs; 2016; 8(3):427-35. PubMed ID: 26854177 [TBL] [Abstract][Full Text] [Related]
18. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products. Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559 [TBL] [Abstract][Full Text] [Related]
19. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892 [TBL] [Abstract][Full Text] [Related]
20. Biosimilar biologic drugs: a new frontier in medical care. Geynisman DM; De Velasco G; Sewell KL; Jacobs I Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]